Phase I study of irinotecan in pediatric patients with malignant solid tumors

American Journal of Pediatric Hematology/Oncology

Volumn 24, Issue 2, 2002, Pages 94-100

  Mugishima, Hideo ^a,b   Matsunaga, Tadashi ^c   Yagi, Keiko ^d   Asami, Keiko ^e   Mimaya, Jun ichi ^f   Suita, Sachiyo ^g   Kishimoto, Tomoko ^d   Sawada, Tadashi ^h   Tsuchida, Yoshiaki ⁱ   Kaneko, Michio ^j  

^a Study Group of Japan for Treatment of Advanced Neuroblastoma   (Japan)

^b NIHON UNIVERSITY   (Japan)

^c CHIBA UNIVERSITY   (Japan)

^d RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^e Niigata Prefectural Cancer Center   (Japan)

^f SHIZUOKA CHILDREN'S HOSPITAL   (Japan)

^g KYUSHU UNIVERSITY   (Japan)

^h KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

ⁱ Gumna Children S Medical Center   (Japan)

^j UNIVERSITY OF TSUKUBA   (Japan)

more..

Author keywords

Advanced neuroblastoma; Irinotecan; Pediatric solid tumors; Phase I study

Indexed keywords

IRINOTECAN;

ADOLESCENT; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; MALE; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; NEUROBLASTOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BONE MARROW DISEASES; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; DIARRHEA; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HEPATITIS, TOXIC; HUMANS; INFUSIONS, INTRAVENOUS; JAPAN; LEIOMYOSARCOMA; MALE; MAXIMUM TOLERATED DOSE; METABOLIC CLEARANCE RATE; NEOPLASM PROTEINS; NEUROBLASTOMA; NEUROECTODERMAL TUMORS, PRIMITIVE; TREATMENT OUTCOME;

EID: 0036174464     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200202000-00007     Document Type: Article

References (31)

1. Kaneda N, Nagata H, Furuta T, et al. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 1990; 50: 1715-20.
2. Verwyij J. Topoisomerase I inhibitors and other new cytotoxic drugs. Eur J Cancer 1995; 5: 828-30.
3. Ohno R, Okada K, Masaoka T, et al. An early phase II study of CPT-11, a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 1990; 8: 1907-12.
4. Futatsuki K, Wakui A, Nakao M, et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Jpn J Cancer Chemother 1994; 21: 1033-8.
5. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small cell lung cancer. J Clin Oncol 1992; 10: 1225-9.
6. Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 1992; 10: 16-20.
7. Takeuchi S, Takamizawa H, Takeda Y, et al. Clinical study of CPT-11, a camptothecin derivative, in gynecological malignancy. Proc Am Soc Clin Oncol 1990; 10: 189.
8. Moertel CG, Schut AJ, Reitemeier RJ, et al. Phase II study of camptothecin in the treatment of advanced gastro-intestinal cancer. Cancer Chemother Rep 1992; 56: 95-101.
9. Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993; 11: 909-13.
10. Rosoff PM, Bayliff S. Successful clinical response to irinotecan in desmoplastic round blue cell tumor. Med Pediatr Oncol 1999; 33: 500-3.
11. Pratt CB, Stewart C, Santana VM, et al. Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 1994; 12: 539-43.
12. Kaneko M, Kaneko S, Ohkawa H. Evaluation of antitumor activities of topoisomerase inhibitors against neuroblastoma. Igaku-no-Ayumi 1993; 165: 875-6.
13. Houghton PJ, Cheschire PJ, Hallman JC, et al. Therapeutic activity of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptotecin. Cancer Res 1993; 53: 2823-9.
14. Komuro H, Li P, Tsuchida Y, et al. Effects of CPT-11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xeno-transplanted neuroblastoma. Med Pediatr Oncol 1994; 23: 487-92.
15. Vassal G, Terrier-Lacombe MJ, Bissery MC, et al. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Br J Cancer 1996; 74: 537-45.
16. Thompson J, Zamboni WC, Cheschire PJ, et al. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res 1997; 3: 423-32.
17. Vassal G, Pondarré C, Cappelli C, et al. DNA-topoisomerase I, a new target for the treatment of neuroblastoma. Eur J Cancer 1997; 33: 2011-5.
18. Choi SH, Tsuchida Y, Yang HW. Oral versus intraperitoneal administration of irinotecan in the treatment of human neuroblastoma in nude mice. Cancer Lett 1998; 124: 15-21.
19. Vassal G, Pondarré C, Bolande I, et al. Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology. Biochimie 1998; 80: 271-80.
20. Furman WL, Stewart CF, Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 1999; 17: 1815-24.
21. Kaneko M, Nishihira H, Mugishima H, et al. Stratification of treatment of stage 4 neuroblastoma patients based on N -myc amplification status. Med Pediatr Oncol 1998; 31: 1-7.
22. Kawa K, Ohnuma N, Kaneko M, et al. Long-term survivors of advanced neuroblastoma with MYCN amplification: A report of 19 patients surviving disease-free for more than 66 months. J Clin Oncol 1999; 17: 3216-20.
23. Zubrod CG, Scheiderman F, Frei E, et al. Cancer: Appraisal of methods for the study of chemotherapy of cancer in man: thiophosphamide. J Chronic Dis 1960; 11: 7-33.
24. Sørensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients: an inter-observer variability study. Br J Cancer 1993; 67: 773-5.
25. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
26. Kunimoto T, Nitta K, Tanaka T, et al. Antitumor activity of 7-ethyl-10- (4-(1-piperidino)-1-piperidino)carbonyl-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987; 47: 5944-7.
27. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization; 1979. Publication No. 48.
28. Stewart CF, Zamboni WC, Crom WR, et al. Topoisomerase I interactive drugs in children with cancer. Invest New Drugs 1996; 14: 37-47.
29. Vassal G. Irinotecan in children: the European experience. Presented at: Conference on Topoisomerase I Targeted Drugs in Pediatric Cancer: Current and Future Directions; September 23-24, 2000; Memphis, TN, U.S.A.
30. Taguchi T, Wakui A, Hasegawa K, et al. Phase I clinical study of CPT-11. Jpn J Cancer Chemother 1990; 17: 115-20.
31. Zamboni WC, Houghton PJ, Thompson J, et al. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts. Clin Cancer Res 1998; 4: 455-62.